The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

News All Time

GLP-1 RAs Reduce Anemia Risk in Patients with Celiac Disease Abigail Brooks, MA

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

1 in 10 People Without Celiac Disease Report Gluten or Wheat Sensitivity Chelsie Derman

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD Walker Redd, MD

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Don't let food poisoning crash your Thanksgiving dinner

Thanksgiving is a time for family, friends and feasting. However, amid the joy of gathering and indulging in delicious food, it is essential to keep food safety in mind. Foodborne illnesses can quickly put a damper on your ...

How the gut builds long-lasting immunity after viral infections

A new study led by University of Toronto researchers has shown that immune cells in the gut follow an atypical pathway to produce antibodies that provide long-term protection against viruses.

New drug offers hope to bladder cancer patients

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

Medications change our gut microbiome in predictable ways, research reveals

Our gut microbiome is made up of trillions of bacteria and other microbes living in our intestines. These help our bodies break down food, assist our immune system, send chemical signals to our brain, and potentially serve ...

Researchers find simple way to make kale healthier by pairing it with oil-based dressings

Think that kale salad you're eating is a superfood? Without the right ingredient it might not be living up to its hype. But don't worry.

How weakness in cell structure affects the host–microbiome relationship

Cells have an internal skeleton that maintains their structure and also drives their movement. Known as the cytoskeleton, this scaffold is composed of a network of dynamic filaments made of a protein called actin.

Scientists map the cells that drive Crohn's disease fistulas

Scientists at the University of Oxford, have identified how rare populations of abnormal cells drive the formation and persistence of fistulas—painful, tunnel-like tracts that develop in around 30% of people with Crohn's ...

AI analyzes multiple physicians' notes to improve diagnosis of complex liver condition

Taking a page from market research tactics, UC San Francisco experts are studying whether artificial intelligence (AI) can improve diagnosis of a complex liver condition by using the clinical notes of multiple providers.

Ultra-processed foods tied to higher rates of early-onset colorectal cancer precursors in adults

Colorectal cancer used to be associated with old age, but diagnoses have become increasingly common in adults aged 50 or younger particularly in high-income countries like the United States. The reason for this trend is unclear, ...

Pill-induced esophagitis: Why your medication could be damaging your throat and what to do about it

Every year, people around the world take an astonishing 3.8 trillion doses of medicine. Most of these medicines are swallowed rather than injected or inhaled, because the oral route is the easiest, safest and most familiar ...

Can't sleep? Your microbiome may play a role

Sleep is a hot commodity—we want it, we need it, but most of us aren't getting enough of it.

Plants adapting to climate change may help IBD treatment

James Cook University (JCU) researchers have discovered that the same chemical compounds produced by mountain-top plants to help them survive climate change in North Queensland may also hold promise for treating inflammatory ...

High-risk individuals who have mild dilation of pancreatic duct have increased risk for pancreatic cancer, study finds

Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030, according to the National Institutes of Health (NIH). The International Cancer of the Pancreas ...

Recommended News For You

New drug combination shows particularly good results in patients with HPV-negative head and neck cancer

Future of Lab-Developed Tests Still Taking Shape

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.

Millions of men could benefit from faster scan to diagnose prostate cancer

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

Could AI plus lasers help catch very early breast cancers?

Recommended Articles For You

Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth  

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment 

Uncovering the Hidden Symptoms of Parathyroid Cancer in Women 

Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality

2.

Novel probes to label macrophages associated with cancer progression using a selective dye

3.

More nonsmokers are getting lung cancer: Oncologist explains why

4.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

5.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

1.

Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology

2.

Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection

3.

A Closer Look at MCV Modules: Features, Functions, and Benefits 

4.

Understanding Colon Cancer: Symptoms, Causes, and Treatment Options 

5.

A New Hope: Exploring the Benefits of Exenteration for Cancer Patients

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Navigating the Complexities of Ph Negative ALL - Part IX

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot